Literature DB >> 33788012

Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism.

Gulsum Gonulalan1,2, Yusuf Tanrıkulu3,4.   

Abstract

BACKGROUND: Subclinical hypothyroidism is related with increased risk of cardiovascular diseases. The decreased levels of dehydroepiandrosterone sulphate (DHEA-S) are associated with hyperlipidemia, atherosclerosis and obesity. The lower levels of DHEA‑S might be an important factor in development of atherosclerosis in subclinical hypothyroidism.
METHODS: A total of 126 patients (62 with subclinical hypothyroidism and 64 healthy individuals) were included in this prospectively designed study between January 2017 and December 2019. All individuals were evaluated according to DHEA‑S levels, carotid intima media thickness (CIMT) and anthropometric measurements. Blood samples were obtained from patients after 8 h fasting. The groups were statistically compared.
RESULTS: The mean ages of control group and patients with subclinical hypothyroidism were 36.9 ± 11.0 years and 39.6 ± 11.0 years, respectively (p = 0.165). The mean waist circumferences in controls and patients were 89 ± 10.7 cm and 91.3 ± 11.1 cm, respectively (p < 0.001). The DHEA‑S levels were 131.04 ± 96.02 µg/dl in patients, and these levels were significantly decreased in patients with subclinical hypothyroidism (p = 0.024). The levels of DHEA‑S were found to be negatively correlated with CIMT (p < 0.001, c = 0.406).
CONCLUSIONS: The early detection of cardiac and metabolic dysfunctions in subclinical hypothyroidism is important to avoid complications. We found a negative correlation between DHEA‑S levels and metabolic and cardiovascular risk factors in subclinical hypothyroidism. We believe that our results would attract more attention to the studies investigating relationships between DHEA‑S levels and cardiovascular complications of subclinical hypothyroidism.
© 2021. Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Endothelial dysfunction; Hypothyroidism; Inflammation; Subclinical atherosclerosis; Thyroid

Mesh:

Substances:

Year:  2021        PMID: 33788012     DOI: 10.1007/s00508-021-01844-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  7 in total

1.  Associated hormonal declines in aging: DHEAS.

Authors:  S Perrini; L Laviola; A Natalicchio; F Giorgino
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

2.  Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway.

Authors:  Yu-dong Wang; Min-fang Tao; Wei-wei Cheng; Xiao-hua Liu; Xiao-ping Wan; KeMi Cui
Journal:  Chin Med J (Engl)       Date:  2012-04       Impact factor: 2.628

3.  Is there a relationship between cardiovascular risk factors and dehydroepiandrosterone sulfate levels in childhood obesity?

Authors:  Nesibe Akyürek; Mehmet Emre Atabek; Beray Selver Eklioglu; Hayrullah Alp
Journal:  J Pediatr Endocrinol Metab       Date:  2015-05       Impact factor: 1.634

4.  Predictors and clinical significance of declining plasma dehydroepiandrosterone sulfate in old age.

Authors:  M H Kähönen; R S Tilvis; J Jolkkonen; K Pitkälä; M Härkönen
Journal:  Aging (Milano)       Date:  2000-08

5.  Relationships between tissue plasminogen activator, steroid hormones and deep vein thrombosis.

Authors:  T Nilsson; G Mellbring; J E Damber
Journal:  Acta Chir Scand       Date:  1985

6.  Inhibition of the conversion of 3T3 fibroblast clones to adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids.

Authors:  G B Gordon; J A Newitt; L M Shantz; D E Weng; P Talalay
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

7.  Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study.

Authors:  E Barrett-Connor; A Ferrara
Journal:  J Clin Endocrinol Metab       Date:  1996-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.